We are live on ! Find out more

Maravai LifeSciences

MRVI

Market cap $1.03B

6.88 USD

+0.19

2.84%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

6.88

0.00

0%

1 day

2.84%

5 days

-2.82%

1 month

21.13%

3 months

38.71%

6 months

118.41%

Year to date

102.35%

1 year

152.94%

5 years

-85.67%

10 years

-76.95%

About: Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

Employees: 415

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel

Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

Maravai LifeSciences Q2 Earnings Call Highlights

Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.

Maravai LifeSciences Q2 Earnings Call Highlights

Zacks Investment Research

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million; Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 milli.

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-579-2543 or 1-785-424-1789 and reference Maravai.

Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026

TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules. The new patent covers TriLink's full suite of CleanCap® capping analogs, including its latest M6 analog. CleanCap technology is a critical com.

TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology

TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale

JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo.

TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th.

Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference

See News Rankings

Price charts implemented using Lightweight Charts™